Photo Credit: Tippapatt

The following is a summary of “Single center evaluation of sensitivity and specificity of CellDetect assay in early bladder cancer patients,” published in the November 2024 issue of Urology by Gao et al. 

Bladder cancer (BC) diagnosis relies on voided urine cytology and cystoscopy, which have significant limitations. 

Researchers conducted a retrospective study to evaluate the sensitivity and specificity of the CellDetect assay in detecting BC. 

They performed B-ultrasonography or computed tomography (CT) scans on patients with hematuria or irritative voiding symptoms between August 2020 and July 2022. Patients without bladder masses were excluded, leaving 148 patients with bladder masses. They measured urine samples using the CellDetect assay, followed by cystoscopy or diagnostic transurethral resection of the bladder tumor. The patients were divided into 2 groups based on previous BC history: group P and group R. The analysis included descriptive statistics and percentages. 

The results showed 115 positive CellDetect cases, with 68 in group P and 47 in group R. A total of 134 malignant tumors were confirmed pathologically. The overall sensitivity and specificity were 82.1% and 64.2%, respectively. In group P, sensitivity and specificity were 81.0% and 50.0%; in group R, they were 85.2% and 83.3%. 

Investigators concluded that the CellDetect assay demonstrated significant diagnostic performance for patients with early-stage BC. It showed good reliability and potential for developing novel methods in clinical practice. 

Source: nature.com/articles/s41598-024-80705-7